Dominic Amj Theuns

List of Publications by Year
in descending order

87	4,245	117453	110170
papers	citations	34 h-index	64 g-index

87	87	87	3277
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. Journal of the American College of Cardiology, 2015, 65, 1605-1615.	1.2	458
2	Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. European Heart Journal, 2014, 35, 1657-1665.	1.0	410
3	The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2012, 60, 1933-1939.	1.2	205
4	Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. European Heart Journal, 2006, 27, 2682-2688.	1.0	201
5	Long-Term Outcome of Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2010, 3, 362-369.	1.6	186
6	Prevention of inappropriate therapy in implantable cardioverter-defibrillators. Journal of the American College of Cardiology, 2004, 44, 2362-2367.	1.2	145
7	Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks. American Heart Journal, 2005, 149, 664-669.	1.2	131
8	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2018, 15, 1515-1522.	0.3	123
9	Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. International Journal of Cardiology, 2015, 195, 126-133.	0.8	120
10	Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 829-835.	2.1	113
11	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm, 2016, 13, 1066-1074.	0.3	92
12	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm, 2014, 11, 1352-1358.	0.3	86
13	Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: Patient outcomes, rate of appropriate and inappropriate interventions, and complications. American Heart Journal, 2013, 166, 496-502.	1.2	82
14	Prevention of inappropriate therapy in implantable defibrillators: A meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. International Journal of Cardiology, 2008, 125, 352-357.	0.8	77
15	The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace, 2011, 13, 62-69.	0.7	77
16	Type-D personality but not implantable cardioverter-defibrillator indication is associated with impaired health-related quality of life 3 months post-implantation. Europace, 2007, 9, 675-680.	0.7	68
17	Usefulness of Left Ventricular Systolic Dyssynchrony by Real-Time Three-Dimensional Echocardiography to Predict Long-Term Response to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2009, 103, 1586-1591.	0.7	66
18	Pre implantation psychological functioning preserved in majority of implantable cardioverter defibrillator patients 12months post implantation. International Journal of Cardiology, 2013, 166, 215-220.	0.8	64

#	Article	IF	Citations
19	Indications and Outcome of Implantable Cardioverterâ€Defibrillators for Primary and Secondary Prophylaxis in Patients with Noncompaction Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2011, 22, 898-904.	0.8	63
20	Quantification of Left Ventricular Systolic Dyssynchrony by Real-Time Three-Dimensional Echocardiography. Journal of the American Society of Echocardiography, 2009, 22, 232-239.	1.2	59
21	Risk of chronic anxiety in implantable defibrillator patients: A multi-center study. International Journal of Cardiology, 2011, 147, 420-423.	0.8	59
22	Clustering of Deviceâ€Related Concerns and Type D Personality Predicts Increased Distress in ICD Patients Independent of Shocks¹. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 20-27.	0.5	51
23	Prevalence and Presentation of Externalized Conductors and Electrical Abnormalities in Riata Defibrillator Leads After Fluoroscopic Screening. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 1059-1063.	2.1	49
24	Anxiety and Risk of Ventricular Arrhythmias or Mortality in Patients With an Implantable Cardioverter Defibrillator. Psychosomatic Medicine, 2013, 75, 36-41.	1.3	49
25	Posttraumatic stress in implantable cardioverter defibrillator patients: The role of pre-implantation distress and shocks. International Journal of Cardiology, 2011, 146, 438-439.	0.8	46
26	Spectral pulsed-wave tissue Doppler imaging lateral-to-septal delay fails to predict clinical or echocardiographic outcome after cardiac resynchronization therapy. Europace, 2007, 9, 113-118.	0.7	45
27	Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. American Journal of Cardiology, 2005, 95, 271-274.	0.7	43
28	Patients' Perspective on Deactivation of the Implantable Cardioverter-Defibrillator Near the End of Life. American Journal of Cardiology, 2013, 111, 1443-1447.	0.7	43
29	Increased Anxiety in Partners of Patients with a Cardioverterâ€Defibrillator: The Role of Indication for ICD Therapy, Shocks, and Personality. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 184-192.	0.5	42
30	Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the Sâ€ICD: Design and Rationale of the EFFORTLESS Sâ€ICD Registry. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 574-579.	0.5	42
31	Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 119, 100-105.	0.7	40
32	Guiding and optimization of resynchronization therapy with dynamic three-dimensional echocardiography and segmental volume-time curves: a feasibility study. European Journal of Heart Failure, 2004, 6, 619-625.	2.9	39
33	Longevity of the Subcutaneous Implantable Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1159-1163.	2.1	37
34	The Prevalence of Early Repolarization in Patients with Noncompaction Cardiomyopathy Presenting with Malignant Ventricular Arrhythmias. Journal of Cardiovascular Electrophysiology, 2012, 23, 938-944.	0.8	35
35	Reverse of Left Ventricular Volumetric and Structural Remodeling in Heart Failure Patients Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2008, 101, 651-657.	0.7	33
36	Ice mapping during cryothermal ablation of accessory pathways in WPW: the role of the temperature time constant. Europace, 2004, 6, 116-122.	0.7	32

#	Article	IF	Citations
37	Analysis of 57,148 Transmissions by Remote Monitoring of Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2009, 32, S63-S65.	0.5	32
38	Comorbidity burden is associated with poor psychological well-being and physical health status in patients with an implantable cardioverter-defibrillator. Europace, 2013, 15, 1468-1474.	0.7	31
39	Insertable cardiac monitors: current indications and devices. Expert Review of Medical Devices, 2019, 16, 45-55.	1.4	30
40	Outcomes of repeat catheter ablation using magnetic navigation or conventional ablation. Europace, 2013, 15, 1426-1431.	0.7	28
41	E-Health to Manage Distress in Patients With an Implantable Cardioverter-Defibrillator. Psychosomatic Medicine, 2014, 76, 593-602.	1.3	27
42	A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 53	0.7	27
43	Evaluation of morphology discrimination for ventricular tachycardia diagnosis in implantable cardioverter-defibrillators. Heart Rhythm, 2006, 3, 1332-1338.	0.3	26
44	Rationale and design of WEBCARE: A randomized, controlled, web-based behavioral intervention trial in cardioverter-defibrillator patients to reduce anxiety and device concerns and enhance quality of life. Trials, 2009, 10, 120.	0.7	26
45	Gender disparities in anxiety and quality of life in patients with an implantable cardioverter-defibrillator. Europace, 2011, 13, 1723-1730.	0.7	25
46	Shock and Patient Preimplantation Type D Personality Are Associated With Poor Health Status in Patients With Implantable Cardioverter-Defibrillator. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 373-380.	0.9	25
47	Remote monitoring of heart failure: benefits for therapeutic decision making. Expert Review of Cardiovascular Therapy, 2017, 15, 503-515.	0.6	23
48	Relation of Symptomatic Heart Failure and Psychological Status to Persistent Depression in Patients With Implantable Cardioverter-Defibrillator. American Journal of Cardiology, 2011, 108, 69-74.	0.7	22
49	Nationwide Fluoroscopic Screening of Recalled Riata Defibrillator Leads in Denmark. Heart Rhythm, 2013, 10, 821-827.	0.3	22
50	The incidence and impact of implantable cardioverter defibrillator shocks in the last phase of life: An integrated review. European Journal of Cardiovascular Nursing, 2018, 17, 477-485.	0.4	22
51	Performance of the Seattle Heart Failure Model in Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2012, 110, 398-402.	0.7	21
52	Procedure- and device-related complications and psychological morbidity in implantable cardioverter defibrillator patients. International Journal of Cardiology, 2013, 168, 606-607.	0.8	21
53	Baseline Predictors of Cardiac Events After Cardiac Resynchronization Therapy in Patients With Heart Failure Secondary to Ischemic or Nonischemic Etiology. American Journal of Cardiology, 2007, 100, 464-469.	0.7	20
54	Poor health status and distress in cardiac patients: the role of device therapy vs. underlying heart disease. Europace, 2013, 15, 355-361.	0.7	20

#	Article	IF	Citations
55	Prediction of Appropriate Defibrillator Therapy in Heart Failure Patients Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2010, 105, 105-111.	0.7	19
56	Longâ€Term Followâ€Up of Prophylactic Implantable Cardioverterâ€Defibrillatorâ€“Only Therapy: Comparison of Ischemic and Nonischemic Heart Disease. Clinical Cardiology, 2011, 34, 761-767.	0.7	17
57	Transvenous Cryothermal Catheter Ablation of a Right Anteroseptal Accessory Pathway. Journal of Cardiovascular Electrophysiology, 2001, 12, 1415-1417.	0.8	16
58	The ischemic etiology of heart failure in diabetics limits reverse left ventricular remodeling after cardiac resynchronization therapy. Journal of Diabetes and Its Complications, 2009, 23, 365-370.	1.2	16
59	Comparative study of the failure rates among 3 implantable defibrillator leads. Heart Rhythm, 2016, 13, 2299-2305.	0.3	16
60	Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator. International Journal of Cardiology, 2018, 272, 97-101.	0.8	15
61	Psychological distress in patients with an implantable cardioverter defibrillator and their partners. Journal of Psychosomatic Research, 2018, 113, 16-21.	1.2	15
62	Symptoms Versus Objective Rhythm Monitoring in Patients with Paroxysmal Atrial Fibrillation Undergoing Pulmonary Vein Isolation. European Journal of Cardiovascular Nursing, 2008, 7, 147-151.	0.4	14
63	Air entrapment causing early inappropriate shocks in a patient with a subcutaneous cardioverter-defibrillator. HeartRhythm Case Reports, 2015, 1, 156-158.	0.2	14
64	Outcome in patients with an ICD incorporating cardiac resynchronisation therapy: Differences between primary and secondary prophylaxis. European Journal of Heart Failure, 2005, 7, 1027-1032.	2.9	13
65	Predictors of Cardiac Events After Cardiac Resynchronization Therapy With Tissue Doppler-Derived Parameters. Journal of Cardiac Failure, 2007, 13, 805-811.	0.7	11
66	Information provision, satisfaction and emotional distress in patients with an implantable cardioverter-defibrillator. International Journal of Cardiology, 2014, 177, 586-588.	0.8	11
67	Trajectories of Patient-Reported Health Status in Patients With an Implantable Cardioverter Defibrillator. American Journal of Cardiology, 2015, 115, 771-777.	0.7	11
68	Implantable cardioverter defibrillator deactivation and advance care planning: a focus group study. Heart, 2020, 106, heartjnl-2019-315721.	1.2	11
69	Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7Âyears' follow-up of the MIDAS cohort. General Hospital Psychiatry, 2020, 66, 154-160.	1.2	11
70	Ventricular tachycardia in ischemic cardiomyopathy; a combined endo-epicardial ablation as the first procedure versus a stepwise approach (EPILOGUE) â€“ study protocol for a randomized controlled trial. Trials, 2015, 16, 487.	0.7	10
71	Patient-Reported Quality of Life as a Predictor of Mortality and Ventricular Tachyarrhythmia's During 7 Yearsâ€™ Follow-Up in Patients With an Implantable Cardioverter Defibrillator (from the MIDAS Study). American Journal of Cardiology, 2019, 123, 605-610.	0.7	9
72	Relation of Statin Therapy to Psychological Functioning in Patients With an Implantable Cardioverter Defibrillator. American Journal of Cardiology, 2013, 111, 1169-1174.	0.7	8

#	Article	IF	Citations
73	Long-term mortality risk in patients with an implantable cardioverterâ€“defibrillator: Influence of heart rate and QRS duration. International Journal of Cardiology, 2014, 175, 560-564.	0.8	6
74	Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 119, 1414-1420.	0.7	6
75	Effect of Cardiac Resynchronization Therapy-Defibrillator Implantation on Health Status in Patients With Mild Versus Moderate Symptoms of Heart Failure. American Journal of Cardiology, 2011, 108, 1155-1159.	0.7	5
76	Application of the heart failure meta-score to predict prognosis in patients with cardiac resynchronization defibrillators. International Journal of Cardiology, 2021, 330, 73-79.	0.8	5
77	Defibrillation threshold testing at implantation: can we predict the patient with a high defibrillation threshold?. Europace, 2010, 12, 309-310.	0.7	4
78	Nationwide Longitudinal Follow-Up ofÂRiata Leads Under Advisory at 3ÂAnnualÂScreenings. JACC: Clinical Electrophysiology, 2017, 3, 887-893.	1.3	4
79	Frequency of Need for Antitachycardia or Antibradycardia Pacing or Cardiac Resynchronization Therapy in Patients With a Single-Chamber Implantable Cardioverter-Defibrillator. American Journal of Cardiology, 2018, 122, 2068-2074.	0.7	4
80	Advance care planning and end-of-life care in patients with an implantable cardioverter defibrillator: The perspective of relatives. Palliative Medicine, 2021, 35, 904-915.	1.3	4
81	Sexâ€specific differences in outcome and risk stratification of ventricular arrhythmias in implantable cardioverter defibrillator patients. ESC Heart Failure, 2021, 8, 3726-3736.	1.4	4
82	An "Atypical" Case of "Typical" AVNRT?. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 630-631.	0.5	2
83	Predicting Early Mortality Among Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2019, 25, 812-818.	0.7	2
84	Letters to the Editor. Journal of Cardiovascular Electrophysiology, 2002, 13, 839-842.	0.8	1
85	The Effect of Elapsed Time from Myocardial Infarction on Mortality and Major Adverse Cardiac and Cerebrovascular Events in ICD Patients. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1448-1455.	0.5	1
86	Questioning the preference for dual- vs. single-chamber implantable defibrillator in primary prevention implantable cardioverter-defibrillator recipients. Europace, 2017, 19, 1416-1417.	0.7	1
87	Patients with congenital heart disease: how to determine the eligibility for implantation of a subcutaneous implantable defibrillator?. Europace, 2015, 17, 1003-1004.	0.7	0